Unibest continuously develops sustainable solutions to address pain points throughout the drug life cycle by helping pharmaceutical companies with investing in new technologies in three areas.

Firstly, investments in advanced manufacturing technologies, such as flow chemistry and mechanochemistry, to streamline production, reduce manufacuturing costs, and accelerate the time-to-market for essential medicines. This increased efficiency allows companies to quickly adapt to changing global demands and policy changes and stay competitive in the market.

Secondly, investments in environmental treatment technologies enable pharmaceutical companies to adopt sustainable practices and effective waste management solutions. By minimizing their ecological footprint, these companies can comply with strict environmental regulations, enhance their public image, and contribute to global conservation efforts. This fosters long-term growth and a positive brand reputation.

Lastly, investments in R&D technologies, including CADD/AIDD, molecular building blocks and chiral sysnthesis platform, facilitate faster drug discovery and development. By leveraging these cutting-edge tools, pharmaceutical companies can bolster their innovation pipeline, rapidly respond to emerging health challenges, and maintain a competitive edge in the industry.